AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Strong Liquidity and Strategic Alliances Underpin Buy Rating for AbCellera Biologics Howard Kim Aug 09, 2024, 11:57 AM Analyst Puneet Souda of Leerink Partners reiterated a Buy rating on AbCellera Biologics (ABCL – Research Report), with a price target of $10.00. Puneet Souda has given his Buy rating due to a combination of factors centering on AbCellera Biologics’ substantial liquidity and its strategic moves to bolster its internal pipeline and foster high-value partnerships. Souda acknowledges ABCL’s shift in focus towards its internal programs, noting the promising progress of its lead assets, ABCL635 and ABCL575, both slated for clinical trial applications by the second quarter of 2025. The company’s disclosure of four T-cell engager assets and their progression through in vivo studies further underscores the potential of AbCellera’s platform. Furthermore, the company’s successful codevelopment ventures, including a partnership with Lilly, and the recent FDA fast track designation of a partnered asset highlight the firm’s ability to attract and maintain strong strategic alliances. Despite a top-line miss, Souda sees AbCellera’s long-term value being driven more by its internal pipeline and strategic collaborations than its service revenue alone. He points out the company’s impressive liquidity position, totaling around $920 million, which he believes provides a significant foundation for upside potential as the company continues to advance its pipeline. With shares trading close to the company’s liquidity value, Souda suggests that the stock has considerable room for growth, bolstered by the company’s platform’s proven capabilities during the COVID-19 pandemic. Consequently, he reaffirms an Outperform rating and a price target of $10. According to TipRanks, Souda is an analyst with an average return of -13.5% and a 35.50% success rate. Souda covers the Healthcare sector, focusing on stocks such as Guardant Health, Illumina, and Exact Sciences.

Ein grosses Problem: 8,59 % Shortquote.

Naja mal abwarten

Erst 2029 oder 2030 wenn überhaupt

AbCellera Biologics (ABCL) Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbCellera Biologics today. The company’s shares closed last Wednesday at $2.63. According to TipRanks.com, Devarakonda is a 3-star analyst with an average return of 3.4% and a 47.3% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Edgewise Therapeutics, and Scholar Rock Holding. The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbCellera Biologics with a $11.50 average price target, representing a 318.2% upside. In a report released today, Bloom Burton also maintained a Buy rating on the stock with a $9.00 price target.